AMTB hydrochloride

AMTB is an antagonist of transient receptor potential melastatin 8 (TRPM8). It inhibits icilin-induced calcium influx with a pIC₅₀ of 6.23. Intravenous administration of AMTB (3 mg/kg) decreases the frequency of volume-induced urinary bladder contractions, without reducing the amplitude of contraction in a rat model. It inhibits the response to noxious bladder stimulation at 10 mg/kg. AMTB also inhibits the sodium channel (Nav) isoforms Nav1.1-1.9 with IC₅₀ values of 2 µM-14.8 µM and decreases viability of MDA-MB-231 and SK-BR-3 breast cancer cells with IC₅₀ values of ~23.7 µM and 17.3 µM, respectively in a TRPM8-independent manner.